Learning Objectives:
1. Review the accumulated clinical experience in treating IPF with antifibrotics.
2. Review the current evidence behind the use of antifibrotic agents in SSc-ILD.
3. Critically evaluate the medical benefits with respect to potential side effects and increase in medical costs associated with the use of antifibrotic agents in SSc.
Session date:
10/22/2019 - 8:30am to 9:30am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Iazsmin Bauer Ventura, M.D., M.Sc.